LOCALLY RECURRENT PROSTATE TUMORS FOLLOWING EITHER RADIATION THERAPY OR RADICAL PROSTATECTOMY HAVE CHANGES IN KI-67 LABELING INDEX, P53 AND BCL-2 IMMUNOREACTIVITY
- 1 May 1998
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 159 (5) , 1437-1443
- https://doi.org/10.1097/00005392-199805000-00004
Abstract
Purpose: We compare the biological phenotype of recurrent prostatic tumors after definitive local therapy (radiation or radical prostatectomy) with that of the same tumors before treatment. Materials and Methods: Cellular proliferation (Ki-67 labeling index), p53 nuclear reactivity and bcl-2 immunoreactivity were determined in pretreatment and posttreatment tumor specimens from 13 patients with local tumor recurrence following radiation, and in 18 patients with local tumor recurrence following radical prostatectomy. Results: Mean Ki-67 labeling index increased approximately 2-fold in locally recurrent tumors after radiation (10.5 versus 5.6%, p = 0.0008) or surgery (6.0 versus 3.2%, p = 0.0025) when compared with pretreatment tumors. We noted p53 nuclear reactivity in a significantly higher proportion of recurrences than in pretreatment tumors following radiation (54 versus 8%, p = 0.032) and surgery (39 versus 5%, p = 0.022). Although bcl-2 immunoreactivity was also seen in a higher proportion of recurrent tumors, this difference did not reach statistical significance for either radiation or surgery. Conclusions: Recurrent tumors following either radiation or surgery differ significantly from the corresponding pretreatment tumors with respect to cellular proliferation and p53 nuclear reactivity.Keywords
This publication has 17 references indexed in Scilit:
- Accelerated Tumor Proliferation Rates in Locally Recurrent Prostate Cancer After Radical ProstatectomyJournal of Urology, 1997
- p53, the Cellular Gatekeeper for Growth and DivisionCell, 1997
- When Checkpoints FailCell, 1997
- Elevated Levels of Apoptosis Regulator Proteins P53 and BCL-2 are Independent Prognostic Biomarkers in Surgically Treated Clinically Localized Prostate CancerJournal of Urology, 1996
- Protein expression of p53, bcl-2, and KI-67 (MIB-1) as prognostic biomarkers in patients with surgically treated, clinically localized prostate cancerSurgery, 1996
- Clinical and Biochemical Evidence of Control of Prostate Cancer at 5 Years After External Beam RadiationJournal of Urology, 1995
- The Value of Serial Prostate Specific Antigen Determinations 5 Years after Radiotherapy: Steeply Increasing Values Characterize 80% of PatientsJournal of Urology, 1993
- Dedifferentiation of locally recurrent prostate cancer after radiation therapy. Evidence for tumor progressionCancer, 1993
- Letters to the editorThe Journal of Pathology, 1992
- Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell deathNature, 1990